Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis

Clinical Rheumatology

Volumn 33, Issue 1, 2014, Pages 21-30

  Ng, Bernard ^a,b   Chu, Adeline ^c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF HOUSTON VICTORIA   (United States)

Author keywords

Computerized records; Disease modifying anti rheumatic drugs; Methotrexate; Rheumatoid arthritis

Indexed keywords

CREATININE; METHOTREXATE; PREDNISONE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; APHTHOUS ULCER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GOVERNMENT; HUMAN; KIDNEY FAILURE; LIP DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MIDDLE AGED; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STEROID THERAPY; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VOMITING;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; DECISION MAKING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALS, VETERANS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84897628643     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2353-9     Document Type: Article

References (29)

1. Aletaha D, Smolen JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 41(12):1367-1374
2. Schnabel A et al (1994) Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 14(1):33-38
3. Verstappen SM et al (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an openlabel strategy trial). Ann Rheum Dis 66(11):1443-1449
4. Grigor C et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430):263-269
5. Visser K, van der Heijde D (2008) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68:1094-1099. doi:10.1136/ ard.2008.092668
6. Singh JA et al (2012) Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64(5):625-639
7. Visser K et al (2009)Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis 68(7):1086-1093
8. VermeerMet al (2011) Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 63(10):2865-2872
9. Wevers-de Boer K et al (2012) Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 71(9):1472-1477
10. Ng B et al (2012) Identification of rheumatoid arthritis patients using an administrative database: a veterans affairs study.Arthritis Care Res 64(10):1490-1496
11. Cannon GWet al (2011) Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res 63(12):1680-1690
12. Charlson ME et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373-383
13. Radner H, Smolen JS, Aletaha D (2011) Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) 50(2):381-388
14. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613-619
15. Kremer JM (1996) Methotrexate update. Scand J Rheumatol 25(6): 341-344
16. Kievit W et al (2010) Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choicebased conjoint analysis. Arthritis Care Res 62(6):842-847
17. Schmajuk G et al (2007) Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 57(6):928-934
18. Schmajuk G et al (2011) Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis inMedicare managed care plans. JAMA 305(5):480-486
19. Widdifield J et al (2011) Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res 63(1):53-57
20. Tutuncu Z et al (2006) Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 65(9): 1226-1229
21. Lacaille D et al (2005) Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 53(2):241-248
22. Sokka Tet al (2009)Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 11(1):R7
23. Felson DT, Anderson JJ, Meenan RF (1992) Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 35(10):1117-1125
24. Forslind K et al (2007) Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 66(1):46-52
25. Pease CT et al (1999) Does the age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors. Rheumatology (Oxford) 38(3):228-234
26. Horton S, Walsh C, Emery P (2012) Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 12(2):235-249
27. Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68(7):1100-1104
28. Aletaha D, Smolen JS (2002) Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 29(8):1631-1638
29. HudsonM, Suissa S (2010) Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care Res 62(6):805-810